What happened: Theramex, a major UK producer of hormone replacement therapy drugs Evorel and Intrarosa, was criticised for systemic failures including outdated prescribing information and unclear pregnancy warnings.
Why it matters:
- Patient safety was compromised due to inaccurate or missing drug information.
- Healthcare providers and patients rely on clear guidance to use HRT drugs safely.
MNN Take: The regulator's censure highlights the importance of timely updates and clear communication in drug safety to protect patients and maintain trust.
Sources: Guardian UK